Figure 1

Upregulation of FMRP by Group I mGluRs was enhanced in ACC from CREB mutant mice, whereas it was not affected in transgenic mice overexpressing a Ca²⁺-insensitive DREAM mutant (TgDREAM). A, The basal levels of FMRP in ACC slices of CREB mutant mice were not affected. B, The increase of FMRP after treatment with Group I mGluR agonist DHPG (100 μM) for 30 min, was enhanced in ACC slices from CREB mutant mice, as compared to wild-type (WT) mice. Representative Western blot (top) and quantification data (bottom) of FMRP are shown for the corresponding treatments. C, The basal levels of FMRP in ACC slices of TgDREAM mice were not affected. D, The increase of FMRP after treatment with Group I mGluR agonist DHPG (100 μM) for 30 min, was not changed in ACC slices from TgDREAM mutant mice, as compared to wild-type (WT) mice. Representative Western blot (top) and quantification data (bottom) of FMRP are shown for the corresponding treatments. Data were normalized by WT control values. ** P < 0.01, compared to control mice; # P < 0.05, compared to WT DHPG treatment. n = 5 mice for each group.